<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658629</url>
  </required_header>
  <id_info>
    <org_study_id>qNIV-E-201</org_study_id>
    <nct_id>NCT03658629</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults</brief_title>
  <official_title>Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 trial to confirm the dose and formulation, demonstrate adjuvant effect, and
      evaluate the safety and tolerability of a single intramuscular injection of Quad-NIV with or
      without Matrix-M1 adjuvant in healthy adults ≥ 65 years of age.

      A total of approximately 1375 subjects will be randomized to seven treatment groups to
      receive Quad-NIV or an active comparator.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, observer-blind, active-controlled, Phase 2 trial will be conducted at
      multiple sites. The composition of the Quad-NIV Influenza Vaccines to be used in this trial
      includes recombinant H1, H3, and two B hemagglutinin proteins for the 2018-2019 Northern
      Hemisphere influenza virus strains.

      Approximately 1375 healthy male and female subjects ≥ 65 years will be randomized into 7
      treatment groups, receiving various formulations of Quad-NIV, with or without Matrix-M1
      adjuvant or one of two active comparator influenza vaccines. Within each site, randomization
      will be stratified by history of receipt of 2017-2018 influenza vaccine. Subjects will
      receive two injections 28 days apart. On Day 0, subjects will receive one of the five
      Quad-NIV formulations or one of the two comparator influenza vaccines. On Day 28, subjects
      will receive either placebo or a licensed influenza vaccine rescue dose, depending on his or
      her initial randomization.

      Subjects will be followed for safety for approximately 6 months, with primary immunogenicity
      results at Day 28.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">April 26, 2019</completion_date>
  <primary_completion_date type="Actual">November 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Day 0 - Day 182</time_frame>
    <description>Solicited local and systemic adverse events over the 7 days post-injection; all adverse events (including adverse changes in clinical laboratory parameters) through 21 days post-injection; and MAEs, SAEs, and SNMCs through 6 months post-injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HAI) Titers of vaccine homologous A and B influenza strains</measure>
    <time_frame>Day 0 - Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>HAI titers of antigenically-drifted influenza strains</measure>
    <time_frame>Day 0 - Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAI titers of vaccine-homologous A and B influenza strains</measure>
    <time_frame>Day 0 - Day 182</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI titers of antigenically-drifted influenza strains</measure>
    <time_frame>Day 0 - Day 182</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">1375</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-1 (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-2 (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-3 (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quad-NIV Preformulated with Increased B HA Adjuvant Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-4 (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quad-NIV without Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-5 (Day 0) and Licensed 2018-2019 Influenza vaccine (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed High-Dose Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 High-Dose Trivalent Vaccine (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quadrivalent Vaccine (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NanoFlu (Quad-NIV)</intervention_name>
    <description>2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine</description>
    <arm_group_label>Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose B</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Increased B HA Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV without Adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matrix-M Adjuvant</intervention_name>
    <description>Adjuvant</description>
    <arm_group_label>Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose B</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Increased B HA Adjuvant Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Licensed High-Dose Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_label>Licensed Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_label>Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose B</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Increased B HA Adjuvant Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone HD</intervention_name>
    <description>2018-2019 Licensed Trivalent Seasonal Influenza Vaccine</description>
    <arm_group_label>Licensed High-Dose Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_label>Quad-NIV without Adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flublok Quadrivalent</intervention_name>
    <description>2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine</description>
    <arm_group_label>Licensed Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_label>Quad-NIV without Adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Clinically-stable adult male or female, ≥ 65 years of age. Subjects may have 1 or more
             chronic medical diagnoses, but should be clinically stable as assessed by:

               -  Absence of changes in medical therapy within 1 month due to treatment failure or
                  toxicity,

               -  Absence of medical events qualifying as serious adverse events within 2 months;
                  and

               -  Absence of known, current, and life-limiting diagnoses which render survival to
                  completion of the protocol unlikely in the opinion of the investigator.

          2. Willing and able to give informed consent prior to trial enrollment, and

          3. Living in the community and able to attend trial visits, comply with trial
             requirements, and provide timely, reliable, and complete reports of adverse events.

        Exclusion Criteria:

          1. Participation in research involving investigational product (drug / biologic / device)
             within 45 days before planned date of first injection.

          2. Participation in any previous Novavax's influenza vaccine clinical trial(s).

          3. History of a serious reaction to prior influenza vaccination, known allergy to
             constituents of licensed comparator vaccines or polysorbate 80.

          4. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza
             vaccine.

          5. Received any vaccine in the 4 weeks preceding the trial vaccination and any influenza
             vaccine within 6 months preceding the trial vaccination.

          6. Any known or suspected immunosuppressive illness, congenital or acquired, based on
             medical history and/or physical examination.

          7. Chronic administration (defined as more than 14 continuous days) of immunosuppressants
             or other immune-modifying drugs within 6 months prior to the administration of the
             trial vaccine. An immunosuppressant dose of glucocorticoid will be defined as a
             systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical,
             inhaled, and nasal glucocorticoids will be permitted.

          8. Administration of immunoglobulins and/or any blood products within the 3 months
             preceding the administration of the trial vaccine or during the trial.

          9. Acute disease at the time of enrollment (defined as the presence of a moderate or
             severe illness with or without fever, or an oral temperature ≥ 38.0°C, on the planned
             day of vaccine administration).

         10. Any condition that in the opinion of the investigator would pose a health risk to the
             subject if enrolled or could interfere with evaluation of the vaccine or
             interpretation of trial results (including neurologic or psychiatric conditions deemed
             likely to impair the quality of safety reporting).

         11. Known disturbance of coagulation.

         12. Suspicion or recent history (within 1 year of planned vaccination) of alcohol or other
             substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Shinde, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novavax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US135</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US045</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US013</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US138</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US025</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US018</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US078</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US108</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US137</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US132</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US071</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US063</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US056</name>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US050</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novavax.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <disposition_first_submitted>December 4, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 28, 2020</disposition_first_posted>
  <last_update_submitted>April 24, 2020</last_update_submitted>
  <last_update_submitted_qc>April 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

